Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05651152 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants
A Phase 1 study, sponsored by Jazz Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 105
- Enrollment target
NCT05651152 is a Phase 1 study that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 105 participants.
The verdict
NCT05651152, a Phase 1 study, has completed, sponsored by Jazz Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 105 participants
- Enrollment target
Study Summary
This Phase 1, double-blind, randomized, placebo-controlled study will characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending nighttime doses of JZP441 in sleep-deprived healthy participants.
Interventions
- DRUG Placebo
- DRUG JZP441
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 105 participants |
| Start Date | 2022-11-28 |
| Est. Completion | 2023-11-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05651152
The ClinicalTrials.gov registry entry for NCT05651152 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05651152 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05651152 about?
NCT05651152 is a clinical study titled "A Study to Investigate The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of JZP441 in Sleep-deprived Healthy Participants". This Phase 1, double-blind, randomized, placebo-controlled study will characterize the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of ascending nighttime doses of JZP441 in sleep-deprived healthy participants.
What is the current status of trial NCT05651152?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 105 participants. The study started on 2022-11-28. Estimated completion is 2023-11-15.
What interventions are being tested in trial NCT05651152?
The interventions under investigation include: Placebo (DRUG), JZP441 (DRUG).
Who is sponsoring clinical trial NCT05651152?
This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.